Viatris (VTRS) Competitors

Viatris (NASDAQ:VTRS) and Legend Biotech (NASDAQ:LEGN) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, community ranking, media sentiment, earnings, risk and institutional ownership.

Does the media favor VTRS or LEGN?

In the previous week, Legend Biotech had 7 more articles in the media than Viatris. MarketBeat recorded 11 mentions for Legend Biotech and 4 mentions for Viatris. Viatris' average media sentiment score of 0.82 beat Legend Biotech's score of 0.27 indicating that Viatris is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viatris	1 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Legend Biotech	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Which has more volatility & risk, VTRS or LEGN?

Viatris has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500. Comparatively, Legend Biotech has a beta of -0.05, indicating that its stock price is 105% less volatile than the S&P 500.

Is VTRS or LEGN more profitable?

Viatris has a net margin of 12.05% compared to Legend Biotech's net margin of 0.00%. Viatris' return on equity of 19.19% beat Legend Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	12.05%	19.19%	7.80%
Legend Biotech	N/A	N/A	N/A

Does the MarketBeat Community favor VTRS or LEGN?

Legend Biotech received 18 more outperform votes than Viatris when rated by MarketBeat users. Likewise, 57.35% of users gave Legend Biotech an outperform vote while only 41.18% of users gave Viatris an outperform vote.

Company	Underperform	Outperform
Viatris	Outperform Votes 21 41.18%	Underperform Votes 30 58.82%
Legend Biotech	Outperform Votes 39 57.35%	Underperform Votes 29 42.65%

Which has higher valuation and earnings, VTRS or LEGN?

Viatris has higher revenue and earnings than Legend Biotech.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$16.26 billion	0.70	$2.08 billion	$1.57	6.02
Legend Biotech	$117 million	97.17	-$446.35 million	N/A	N/A

Do institutionals and insiders believe in VTRS or LEGN?

74.7% of Viatris shares are owned by institutional investors. Comparatively, 38.9% of Legend Biotech shares are owned by institutional investors. 0.3% of Viatris shares are owned by insiders. Comparatively, 0.0% of Legend Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Do analysts recommend VTRS or LEGN?

Viatris presently has a consensus target price of $12.67, suggesting a potential upside of 34.18%. Legend Biotech has a consensus target price of $77.90, suggesting a potential upside of 13.05%. Given Viatris' higher possible upside, equities analysts clearly believe Viatris is more favorable than Legend Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.14
Legend Biotech	0 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.87

Summary

Viatris beats Legend Biotech on 10 of the 16 factors compared between the two stocks.